Role of ursodeoxycholic acid in pediatric cholestatic disease;Rôle de l'acide ursodésoxycholique dans le traitement des cholestases de l'enfant

Gastroenterologie Clinique et Biologique

Volumn 28, Issue 10 I, 2004, Pages 852-859

  El Rifai, Nahida ^a   Gottrand, Frédéric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

URSODEOXYCHOLIC ACID;

ALAGILLE SYNDROME; BILE DUCT ATRESIA; CHILD; CHILDHOOD DISEASE; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; REVIEW; SCLEROSING CHOLANGITIS; TOTAL PARENTERAL NUTRITION;

EID: 7044227444     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(04)95147-0     Document Type: Review

References (75)

1. Beuers U, Boyer JL, Paumgartner G. Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 1998;28:1449-55.
2. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-90.
3. Chazouillères O, Wendum D. Maladies des voies biliaires intrahépatiques: diagnostic et principes du traitement. Gastroenterol Clin Biol 2003;27:307-18.
4. Lacaille F. Les acides biliaires et leur utilisation thérapeutique chez l'enfant. Arch Pédiatr 1995;2:1200-8.
5. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, et al. Ursodeoxycholic acid therapy in pédiatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997;25:519-23.
6. Poupon R, poupon RE. Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmac Ther 1995;66:1-15.
7. Okolicsanyi L, Lirussi F, Strazzabosco M, Jemmolo RM, Orlando R, Nassuato G, et al. The effect of drugs on bile flow and composition. An overview. Drugs 1986;31:430-48.
8. Simoni P, Sabatini L, Baraldini M, Mirasoli M, Roda A, Roda E. Pharmacokinetics and bioavailability of four modified-releas ursodeoxycholic acid preparations for once-a-day administration. Int J Clin Pharmacol Res 2002;22:37-45.
9. Sauer P, Benz C, Rudolph G, Kl̈ters-Plachky PK, Stremmel W, Stihl A. Influence of cholestasis on absorption of Ursodeoxycholic acid. Dig Dis Sci 1999;44:817-22.
10. Walker S, Rudolph G, Raedsch R, Stiehl A. Intestinal absorption of Ursodeoxycholic acid in patients with extrahepatic biliary obstruction and bile drainage. Gastroenterology 1992;102:810-5.
11. Lanzini A, Facchinetti D, Pigozzi MG, Bettini L, Muiesan G. Bestbuy regimen of Ursodeoxycholic acid for patients with gallstones. Scand J Gastroenterol 1991;26:551-56.
12. Van De Meeberg PC, Houwen RHJ, Sinaasappel M, Heijerman HGM, Bijleveld CHMA, Vanberge-Henegouwen P. Low-dose versus high-dose Ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Scand J Gastroenterol 1997;32:369-73.
13. Gilger MA, Gann ME, Opekun AR, Gleason WA. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J Pediatr Gastroenterol Nutr 2000;31:136-41.
14. Podda M, Ghezzi C, Battezzati PM, Bertolini A, Crosignani A, Petroni ML, et al. Effect of different doses of Ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989;12:59S-69S.
15. Angulo P. Use of Ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep 2002;4:37-44.
16. Joo SS, Kang HC, Won TJ, Lee DI. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1beta and nitric oxide in rat microglia. Arch Pharm Res 2003;26:1067-73.
17. Kumar D, Tandon RK. Use of Ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol 2001;16:3-14.
18. Podda M, Crosignani A, DeValle G, Battezzati PM, Quagliuolo M, Fragiacomo L, et al. Treatment of hepatocellular cholestatic liver disease. In : Gentilini P, et al., editors. Cholestasis. Amsterdam: Elsevir Science BV 1994:253-66.
19. Iser JH, Sali A. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use. Drugs 1981;21:90-119.
20. Bousvaros A, Werlin S, Tolia V, Raynaud S, Ferry G, Kirschner B. Effects of Ursodeoxycholic acid on biochemical parameters in children with primary sclerosing cholangitis. J Pediatr Gastroenterol Nutr 1995;21:325 (abstract).
21. Kay MH, Wyllie R, Steffen RM. Use of ursodeoxycholic acid in the treatment of arteriohepatic dysplasia. Clin Pediatr 1996;35:593-6.
22. Lanzarotto F, Panarotto B, Sorbara R, Panteghini M, Pagani F, Sosta S, et al. Effect of long-term simvastatin administration as an adjunct to ursodeoxycholic acid: evidence for a synergestic effect on biliary bile acid composition but not on serum lipids in humans. Gut 1999;44:552-6.
23. Roberts EA. The jaundiced baby. In : Kelly DA, ed. Diseases of the liver and biliary system in children. London: Blackwell Science, 1999:11-45.
24. Chardot C, Carton M, Spire-Benelac N, Le Pommelet C, Golmard JL, Auvert B. Epidemiology of biliary atresia in France: a national study 1986-96. J Hepatol 1999;31:1006-13.
25. Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gastroenterol Nutr 2003;37:4-21.
26. Meyers RL, Book LS, O'Gorman MA, Jackson WD, Black RE, Johnson DG, et al. High-dose steroids, ursodeoxycholic acid and chronic intravenous antibiotics improve flow after Kasai procedure in infants with biliary atresia. J Pediatr Surg 2003;38:406-11.
27. Nittono H, Tokita A, Hayashi M, Nakatsu N, Obinata K, Watanabe T, et al. Ursodeoxycholic acid in biliary atresia. Lancet 1987;5:1324.
28. Petersen C, Ure BM. What's new in biliary atresia? Eur J Pediatr Surg 2003;13:1-6.
29. Nittono H, Tokita A, Hayashi M, Watanabe T, Obinata K, Nakatsu T, et al. Ursodeoxycholic acid therapy in the treatment of biliary atresia. Biomed Pharmacother 1989;43:37-41.
30. Ullrich D, Rating D, Schröter W, Hanefeld F, Bircher J. Treatment with ursodeoxycholic acid renders children with biliary atresia suitable for liver transplantation. Lancet 1987;5:1324.
31. Yamashiro Y, Ohtsuka Y, Shimizu T, Nittono H, Urao M, Miyano T, et al. Effect of ursodeoxycholic acid treatment on essential fatty acid deficiency in patients with biliary atresia. J Pdiatr Surg 1994;29:425-8.
32. Watson GH, Miller V. Arteriohepatic sysolasia. Familial pulmonary arterial stenosis with neonatal liver disease. Arch Dis Child 1973;48:459-66.
33. Alagille D, Odièvre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral anomalies, retarded physical, mental, and sexual development, and cardiac murmur. J Pediatr 1975;86:63-71.
34. Kamath BM, Stolle C, Bason L, Colliton RP, Piccoli DA, Spinner NB, Krantz ID. Craniosynostosis in Alagille syndrome. Am J Med Genet 2002;112:176-80.
35. Silberbach M, Lashley D, Relier MD, Kinn WF Jr, Terry A, Sunderland CO. Arteriohepatic dysplasia and cardiovascular malformations. Am Heart J 1994;127:695-9.
36. Hoffenberg EJ, Narkewicz MR, Sondheimer JM, Smith DJ, Silverman A, Sokol RJ. Outcome of syndromic paucity of interlobular bile ducts (Alagille syndrome) with onset of cholestasis in infancy. J Pediatr 1995;127:220-4.
37. Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 2001;49:431-5.
38. Vandenberg M, Rings E, Stokkers P. Genetic basis of Alagille syndrome. J Pediatr Gastroenterol Nutr 1998;27:370-1.
39. Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritis and xanthomas in Alagille syndrome. Hepatology 2002;35:1501-6.
40. Balistreri WF, A-Kader H, Setchell KDR. Ursodeoxycholic acid therapy in patients with Alagille syndrome: results of multicenter pilot trial. Pediatr Res 1991;29:99 (abstract).
41. Clerici C, Gentili G, Dozzini G, Distrutti E, Solinas A, Vedovelli A, et al. Chronic therapy with ursodeoxycholic acid in a child with Alagille syndrome. Pediatr Med Chir 1993;15:521-3.
42. Krawinkel MB, Sanier R, Oldigs HD. Ursodeoxycholic acid: effect on xanthomas in Alagille-Watson syndrome. J Pediatr Gastroenterol Nutr 1994;19:476-7.
43. Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children. J Pediatr 1994;124:49-56.
44. Sisto A, Feldman P, Garel L, Seidman E, Brochu P, Morin CL. Primary sclerosing cholangitis in children : study of 5 cases and review of the litterature. Pediatrics 1987;80:918-23.
45. Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-7.
46. Ismail H, Kalicinski P, Markiewicz M, Jankowsa I, Pawlowska J, Kluge P, et al. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr Tansplam 1999;3:219-24.
47. Jacquemin E, Dumont M, Bernard O, Erlinger S, Hadchouel M. Evidence for defective primary bile acid secretion in children with progressive familial intrahepatic cholestasis (Byler disease). Eur J Pediatr 1994;153:424-28.
48. Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, et al. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 1996;23:904-8.
49. Soubrane O, Gauthier F, DeVictor D, Bernard O, Valayer J, Houssin D, et al. Orthotopic liver transplantation for Byler disease. Transplantation 1990;50:804-806.
50. Socha P, Nowicka G, Jankowska I, Rujner J, Pawlowska J, Socha J. Apolipoprotein E polymorphism in Alagille syndrome and progressive familial intrahepatic cholestasis. Dig Dis Sci 2000;45:675-9.
51. Nathanson MH, Boyer JL. Mechanisms and regulation of bile acid secretion. Hepatology 1991;14:551-66.
52. Setchell KDR, O'Connell NC. Inborn errors in bile acid synthesis. In : Suchy FJ, Sokol RJ, Balistreri WF, ed. Disorders of bile acid synthesis and metabolism: a metabolic basis for liver disease. Philadelphia: Lippincott Williams and Wilkins, 2001:701-34.
53. Daugherty CC, Setchell KDR, Heubi JE, Balistreri WF. Resolution of liver biopsy alterations in three siblings with bile acid treatment of an inborn error of bile acid metabolism (D4-3-Oxosteroid 5b-reductase deficiency). Hepatology 1993;18:1096-101.
54. Lykavieris P, Bernard O, Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996;75:67-70.
55. Furuya KN, Roberts EA, Canny GJ, Phillips MJ. Neonatal hepatitis syndrome with paucity of interlobular bile ducts in cystic fibrosis. J Pediatr Gastroenterol Nutr 1991;12:127-30.
56. Willi UV, Reddish JM, Teele R. Cystic fibrosis: its characteristics appearance on abdominal sonography. Am J Roentgenol 1980;134:1005-10.
57. Santamaria F, Vajro P, Oggero V, Greco L, Angelillo M, Carrillo F, et al. Volume and emptying of the gallbladder in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1990;10:303-6.
58. Bilton D, Fox R, Webb AK, Lawler W, McMahon RF, Howat JM. Pathology of common bile duct stenosis in cystic fibrosis. Gut 1990;31:236-8.
59. O'Brien S, Keogan M, Casey M, Duffy G, McErlean D, Fitgerald MX, et al. Biliary complications of cystic fibrosis. Gut 1992;33:387-91.
60. De Arce M, O'Brien S, Hegarty J, O'Mahoney SM, Cashman SM, Martinez A, et al. Deletion delta F508 and clinical expression of cystic fibrosis-related liver disease. Clin Genet 1992;42:271-2.
61. Colombo C, Apostolo MG, Ferrari M, Seia M, Genoni S, Giunta A, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr 1994;124:393-9.
62. Cotting J, Lentze MJ, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990;31:918-21.
63. Colombo C, Setchell KD, Podda M, Crosignani A, Roda A, Curcio L, et al. Effect of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990;117:482-9.
64. Lepage G, Paradis K, Lacaille F, Sénéchal L, Ronco N, Champagne J, et al. Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis. J Pediatr 1997;130:52-8
65. Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996;23:1484-90.
66. Lindblad A, Glaumann H, Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998;27:166-74.
67. Lenaerts C, Lapierre C, Patriquin H, Bureau N, Lepage G, Harel F, et al. Surveillance for cystic fibrosis-associated hepatobiliary disease: early ultrasound changes and predisposing factors. J Pediatr 2003; 143:343-50.
68. Nousia-Aranitakis S, Fotoulaki M, Economou H, Xefteri M, Gallia Tsinopoulou A. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001;32:324-8.
69. Beale EF, Nelson RM, Bucciarelli RL, Donnelly WH, Eitzman DV. Intrahepatic cholestasis associated with parenteral nutrition in premature infants. Pediatrics 1979;64:342-7.
70. Tzakis AJ, Todo S, Reyes J. Clinical intestinal transplantation: focus on complications. Transplant Proc 1992;24:1238-40.
71. Hofmann AF. Defective biliary secretion during total parenteral nutrition: probable mechanisms and possible solutions. J Pediatr Gastroenterol Nutr 1995;20:376-90.
72. Duerksen DR, Van Aerde JE, Gramlich L, Meddings JB, Chan G, Thomson ABR, et al. Intravenous ursodeoxycholic acid reduces cholestasis in parenterally fed newborn piglets. Gastroenterology 1996:111:1111-7.
73. Lindor KD, Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition associated cholestasis. A case report. Gastroenterology 1991;101:250-53.
74. Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term TPN: a pilot study. Gastroenterology 1996;111:716-9.
75. Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L. Parenteral nutrition-associated cholestasis in preterm neonates: evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab 1999;12:549-53.